UGT1A1 and breast cancer: Considering the relationship between UGT1A1 polymorphisms, increased toxicities, and subsequent therapy discontinuation, it raises the possibility that pharmacogenomics may play a role in the adverse outcomes experienced by African American women with breast cancer.